Approval · Notice of Compliance 25120 · 2021

LIBRELA: Notice of Compliance 25120

Issued February 1, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 25120
Date: February 1, 2021
Company: Zoetis Canada IncKirkland, Quebec, Canada
Product type: Veterinary
Submission: New Drug Submission (NDS)
Submission class: Other

Products in this notice

Brand	DIN	Status today
LIBRELA	02511797	Marketed
LIBRELA	02511800	Marketed
LIBRELA	02511819	Marketed
LIBRELA	02511827	Marketed
LIBRELA	02511835	Marketed

Medicinal ingredients

BEDINVETMAB 5 MG per ML
BEDINVETMAB 10 MG per ML
BEDINVETMAB 15 MG per ML
BEDINVETMAB 20 MG per ML
BEDINVETMAB 30 MG per ML